Market Intelligence Center  May 22  Comment 
Eleven Biotherapeutics EBIO suffered a huge setback with its lead pipeline candidate failing in a late-stage study. Meanwhile, companies like bluebird BLUE, Agios AGIO and Acceleron XLRN all got encouraging news on the regulatory front. Achillion...
Motley Fool  May 20  Comment 
Achillion Pharmaceuticals, Inc. investors are disappointed that Johnson & Johnson isn't buying the company outright.
Benzinga  May 20  Comment 
Lpath, Inc. (NASDAQ: LPTN) shares dropped 75.44 percent to $0.420 after the company announced its plans to cut jobs as its multicenter, Phase 2 Nexus clinical trial evaluating iSONEP™ in patients with wet age-related macular degeneration did...
TheStreet.com  May 20  Comment 
NEW YORK (TheStreet) -- Shares of Achillion Pharmaceuticals are plummeting, down 12.83% to $9.31 in early market trading Wednesday, as the company gets downgraded by analysts at JMP Securities to "market perform" from "market outperform" on...
Benzinga  May 20  Comment 
Analysts at JMP Securities downgraded Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) from Market Outperform to Market Perform and removed the price target of $24.00. Achillion Pharmaceuticals shares have gained 292.65 percent over the past 52...
Benzinga  May 20  Comment 
GenEng News  May 20  Comment 
Johnson & Johnson’s Janssen Pharmaceuticals will co-develop at least one of Achillion Pharmaceuticals’ lead hepatitis C virus (HCV) drug candidates and possibly more, under a worldwide license and collaboration agreement that could generate up...
TheStreet.com  May 20  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Achillion Pharmaceuticals was upgraded at William Blair to outperform. Twelve-month price target is $18. Company monetized its HCV franchise and will focus on Factor D, William Blair said. Achillion...

You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki